Mindstate Design Labs · Dec 2025
Company press release announcing Graeme Bell as an independent board director; also reiterates the Osmanthus platform and provides a public contact email.
Clinical-stage AI neuroengineering platform
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Clinical-stage AI neuroengineering and drug development company building programmable psychoactive therapeutics for mental health. Primary product is the Osmanthus platform and lead asset MSD-001, which map subjective trip-report data to receptor biology to design specific emotional and cognitive states.
Primary product
Osmanthus platform and lead asset MSD-001
Founded
2021
Headquarters
South San Francisco, California, United States
Team size
11-50
Work style
Remote
Industry
Biotechnology
Sub-industry
Clinical-stage neuroengineering / psychedelic therapeutics
Offices
Open Positions
1 job at Mindstate Design Labs
Open Application
RemoteFuture OpportunitiesRemote (United States)5mo ago
Remote